Bristol-Myers Squibb Plans to Sell Celgene's Otezla in Attempt to Expedite Acquisition
“Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene,” the company stated. “The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis.”